BofA lowered the firm’s price target on Sarepta (SRPT) to $179 from $210 and keeps a Buy rating on the shares. Following the news of the departure of Peter Marks from the FDA’s Center for Biologics ...

The tragic death of the 16-year-old boy came as a result of acute liver failure, which is a known side effect of Elevidys and ...

Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...

Shares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...

RBC Capital analyst Brian Abrahams downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161. The ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent ...

The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, ...

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Elevidys, Sarepta’s gene therapy for DMD, has demonstrated significant commercial success since receiving expanded label approval for patients aged 6 and older. The therapy has exceeded revenue ...

Elevidys, Sarepta’s gene therapy for DMD, has demonstrated significant commercial success since receiving expanded label approval for patients aged 6 and older. The therapy has exceeded revenue ...